Alira Health

Alira Health

Alira Health Announces the Spin-Off of Product Development Laboratory

Lab Will Continue to Innovate in Wound Care and Chronic Inflammatory Diseases as a Separate Company, ProDevLabs

Framingham, Mass. – Alira Health, a global healthcare advisory, clinical research and technology company, announces the spin-off of ProDevLabs, a new company led by Dr. Mitchell Sanders, PhD, a former Alira Health executive.

 

News
Published on:
May 2, 2023
Dr. Sanders is a visionary scientist who launched this product development lab at Alira Health in 2015. It’s been a pleasure working with Mitch and nurturing the growth of the lab to become a successful business.
Gabriele Brambilla CEO

ProDevLabs will continue its groundbreaking work as a product development lab focused on chronic inflammatory diseases, including wound care, cancer, infections/biofilms, and neuropathologies such as traumatic brain injury, Alzheimer’s, and Parkinson’s.

“Dr. Sanders is a visionary scientist who launched this product development lab at Alira Health in 2015,” said Gabriele Brambilla, CEO and Co-Founder of Alira Health. “It’s been a pleasure working with Mitch and nurturing the growth of the lab to become a successful business.”

“ProDevLabs will continue its growth trajectory as a best-in-class CRO,” said Dr. Sanders. “We plan to add new talent and resources to accommodate our clients’ needs. I am grateful to Alira Health for the opportunity to grow these services over the last eight years and look forward to maintaining our close relationship with Alira Health.”

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

Related news

Webinars February 5, 2024
What Comes After the mRNA Vaccines?
In the third episode of VacciTalks, we’ll discuss these new alternatives to mRNA vaccines and the promise they hold.
Drug Development Vaccines
News November 21, 2023
Alira Health to Present at the Piper Sandler 35th Annual Healthcare Conference
Alira Health announced that Gabriele Brambilla, Alira Health’s Chief Executive Officer and Co-Founder, and Piergiulio Lauriano, Chief Strategy Officer at Alira Health, will present(...)
Healthcare Technology Life Sciences
Scientific Articles November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Articles October 16, 2023
Biotechs on the Rise
In the final article of our Biotech series, Joris Pezzini talks about the evolution of biotechs in the face of challenges and the drivers for future success.
Biotech Drug Development
Scientific Articles September 20, 2023
Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates
Our expert CMC team addresses the manufacturing challenges of ADCs in “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates.”
CMC Drug Development
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma Press Release
Articles August 28, 2023
Mandatory Patient-Focused Listening Sessions with CMS: What Manufacturers Need to Know
To learn about patient-focused listening sessions, their potential impact, and how manufacturers can prepare, we spoke with our experts.
Drug Development Patient Advocacy Patient Engagement
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.